Product Description
Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, lung and cervical cancer. It may also be used to treat other cancers. It is best to read this information with our general information about chemotherapy and the type of cancer you have. (Sourced from: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/cisplatin)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 218
Highest Development Phases
Phase 3: Adenocarcinoma|Basal Cell Carcinoma|Biliary Tract Cancer|Bladder Cancer|Cervical Cancer|Cholangiocarcinoma|Endometrial Cancer|Esophageal Cancer|Fallopian Tube Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Hodgkin Lymphoma|Mesothelioma|Muscle Cancer|Nasopharyngeal Cancer|Neuroblastoma|Non-Small-Cell Lung Cancer|Oropharyngeal Cancer|Other|Ovarian Cancer|Papillary Carcinoma|Peritoneal Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Uterine Cancer
Phase 2: Anal Cancer|Anus Cancer|Bile Duct Cancer|Colorectal Cancer|Deafness|Extranodal NK-T-Cell Lymphoma|Glioma|Hearing Loss|Hepatocellular Carcinoma|Hypopharyngeal Cancer|Laryngeal Cancer|Lung Cancer|Lymphatic Metastasis|Mouth Cancer|Multiple Myeloma|Neuroendocrine Carcinoma|Oncology Solid Tumor Unspecified|Oncology Unspecified|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Papilloma|Penile Cancer|Pleural Cancer|T-Cell Peripheral Lymphoma|Triple Negative Breast Cancer|Vulvar Cancer
Phase 1: Epilepsy|Healthy Volunteers|Lymphoma, B-Cell|Muscle Spasticity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HR-NBL2 | P3 |
Active, not recruiting |
Neuroblastoma |
2031-09-24 |
|
| R01CA181745 | P2 |
Not yet recruiting |
Cervical Cancer|Uterine Cancer |
2031-04-07 |
|
| NRG-HN009 | P3 |
Recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma|Oropharyngeal Cancer |
2031-02-09 |
|
| RELATIVITY1093 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2030-07-30 |